These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33783230)

  • 1. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
    Scherrer E; Rau R; Lorenzi M; Shui I; Townson S; Larkin J
    Future Oncol; 2021 Jul; 17(20):2683-2692. PubMed ID: 33783230
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
    Mallardo D; Fordellone M; White A; Vowinckel J; Bailey M; Sparano F; Sorrentino A; Mallardo M; Facchini BA; De Filippi R; Ferrara G; Vanella V; Beeler K; Chiodini P; Cesano A; Warren S; Ascierto PA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
    Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
    Front Immunol; 2021; 12():691032. PubMed ID: 34290710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
    Front Immunol; 2021; 12():672521. PubMed ID: 34177913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
    Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
    Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
    Tjulandin S; Demidov L; Moiseyenko V; Protsenko S; Semiglazova T; Odintsova S; Zukov R; Lazarev S; Makarova Y; Nechaeva M; Sakaeva D; Andreev A; Tarasova A; Fadeyeva N; Shustova M; Kuryshev I
    Eur J Cancer; 2021 May; 149():222-232. PubMed ID: 33872982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
    Chatziioannou E; Higuita LMS; Kreft S; Kandolf L; Dujovic B; Reinhardt L; Tamara E; Marquez-Rodas I; Fortuna ARFP; Nübling A; Niessner H; Forschner A; Garbe C; Popovic A; Mirjana B; Meier F; Eigentler T; Leiter U; Flatz L; Sinnberg T; Amaral T
    ESMO Open; 2024 Aug; 9(8):103661. PubMed ID: 39096893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
    van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
    Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
    Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.